Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in L… (NCT07716345) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
100 participantsStarted 2026-10-01
Plain-language summary
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing. Substantial variation exists among patients in their tumor response to the same conversion therapy regimen, and current pretreatment imaging assessment does not adequately capture this inter-individual variability. We hypothesize that baseline tumor viscoelastic parameters measured by three-dimensional magnetic resonance elastography (3D-MRE) differ substantially across patients, and that this inter-individual heterogeneity may be associated with differential response to conversion therapy. This study aims to prospectively evaluate the association between baseline 3D-MRE-derived tumor viscoelastic parameters and pathological response as well as surgical conversion outcomes across patients with liver cancer receiving conversion therapy.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18-75 years
* Pathologically or radiologically confirmed diagnosis of initially unresectable liver cancer (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or liver metastasis)
* Planned to receive conversion therapy with the intent of achieving surgical resectability
* Child-Pugh class A or B liver function (for patients with primary liver cancer)
* ECOG performance status 0-1
* At least one measurable lesion per RECIST 1.1
* Able to undergo 3D-MRE examination prior to conversion therapy
* Provision of signed and dated informed consent
Exclusion Criteria:
* Contraindication to MRI
* Child-Pugh class C liver function (for patients with primary liver cancer)
* Uncontrolled ascites, hepatic encephalopathy, or variceal bleeding within 3 months prior to enrollment
* Other concurrent active malignancy
* Severe comorbidities precluding conversion therapy or surgery
* Pregnant or breastfeeding women
* Anticipated poor compliance with repeated MRE examinations or follow-up
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Objective Response Rate (ORR) after conversion therapy
Timeframe: At the time of post-conversion therapy imaging evaluation (approximately 8-12 weeks after treatment initiation)
Trial details
NCT IDNCT07716345
SponsorSecond Affiliated Hospital of Xi'an Jiaotong University